<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age/><report-id>DE-AMGEN-DEUCT2013005137</report-id><gender>female</gender><reactions><reaction>Cholangitis</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>panitumumab</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>GEMCITABINE</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>CISPLATIN</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Bile duct cancer</indication></indications><outcomes><outcome>Required Inpatient Hospitalization</outcome></outcomes><country>Germany</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>864720_123</messagenumb>
		<messagesenderidentifier>AMGENSAFETY</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125152046</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>DE-AMGEN-DEUCT2013005137</safetyreportid>
		<primarysourcecountry>DE</primarysourcecountry>
		<occurcountry>DE</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-25</transmissiondate>
		<reporttype>2</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2013-01-22</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-22</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>DE-AMGEN-DEUCT2013005137</companynumb>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>DE</reportercountry>
			<qualification code="1">Physician</qualification>
			<studyname>Panitumumab in combination with cisplatin/gemcitabine chemotherapy in patients with cholangiocarcino</studyname>
			<sponsorstudynumb>20080683</sponsorstudynumb>
			<observestudytype>1</observestudytype>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>AMGENSAFETY</senderorganization>
			<senderdepartment>Amgen Global Safety</senderdepartment>
			<sendergivename>Paul</sendergivename>
			<senderfamilyname>Eisenberg</senderfamilyname>
			<senderstreetaddress>One Amgen Center Drive</senderstreetaddress>
			<sendercity>Thousand Oaks</sendercity>
			<senderstate>California</senderstate>
			<senderpostcode>91320</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>8054471000</sendertel>
			<sendertelcountrycode>1</sendertelcountrycode>
			<senderfax>8054994495</senderfax>
			<senderfaxcountrycode>1</senderfaxcountrycode>
			<senderemailaddress>dsstriage@amgen.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receivergivename>Bill</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receivercountrycode>US</receivercountrycode>
			<receiveremailaddress>wtaylor@oc.fda.gov</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>PRIVACY</patientinitial>
			<patientsex code="2">Female</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Bile duct cancer</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Cholangitis</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Cholangitis</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Cholangitis</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20130121</reactionstartdate>
				<reactionfirsttime>60</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>11</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>panitumumab</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationnumb>125-147</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Amgen</drugauthorizationholder>
				<drugstructuredosagenumb>9</drugstructuredosagenumb>
				<drugstructuredosageunit code="007"/>
				<drugdosagetext>9 mg/kg, UNK</drugdosagetext>
				<drugdosageform normalized="solution for injection">Solution for injection</drugdosageform>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Bile duct cancer</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-11-22</drugstartdate>
				<drugstartperiod>60</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod>11</druglastperiod>
				<druglastperiodunit>804</druglastperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2013-01-10</drugenddate>
				<drugtreatmentduration>50</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="5">Unknown</actiondrug>
				<activesubstance>
					<activesubstancename>panitumumab</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Cholangitis</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Cholangitis</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>GEMCITABINE</medicinalproduct>
				<drugstructuredosagenumb>1000</drugstructuredosagenumb>
				<drugstructuredosageunit code="009"/>
				<drugdosagetext>1000 mg/m2, UNK</drugdosagetext>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Bile duct cancer</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-11-22</drugstartdate>
				<drugstartperiod>60</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod>4</druglastperiod>
				<druglastperiodunit>804</druglastperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2013-01-17</drugenddate>
				<drugtreatmentduration>57</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<activesubstance>
					<activesubstancename>GEMCITABINE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>CISPLATIN</medicinalproduct>
				<drugstructuredosagenumb>25</drugstructuredosagenumb>
				<drugstructuredosageunit code="009"/>
				<drugdosagetext>25 mg/m2, UNK</drugdosagetext>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Bile duct cancer</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-11-22</drugstartdate>
				<drugstartperiod>60</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod>4</druglastperiod>
				<druglastperiodunit>804</druglastperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2013-01-17</drugenddate>
				<drugtreatmentduration>57</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<activesubstance>
					<activesubstancename>CISPLATIN</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>The following event was received from a Non Amgen Sponsored Trial (Investigator Sponsored Study).This female subject was participating in a randomized clinical phase II study of <Semaphore x="978477" class="Medicine" value="panitumumab" score="0.74" ID="252216">panitumumab </Semaphore>in <Semaphore x="1801472" class="Procedure" value="Combination Chemotherapy" score="1.00" ID="C191">combination with cisplatin/gemcitabine <Semaphore x="2854686" class="MedDRA LLT" value="Chemotherapy" score="1.00" ID="10061758">chemotherapy </Semaphore></Semaphore>in patients with cholangiocarcinomas and developed <Semaphore x="1772585" class="Disease or Finding" value="Cholangitis" score="1.00" ID="C26718">cholangitis</Semaphore>.The subjects medical history included <Semaphore x="1772231" class="Disease or Finding" value="Cholangiocarcinoma" score="1.00" ID="C4436">cholangiocarcinoma</Semaphore>. No previous treatment for the condition under study and no concomitant medications were reported.The subject received the first dose of open label investigational product <Semaphore x="978477" class="Medicine" value="panitumumab" score="0.74" ID="252216">panitumumab </Semaphore>in combination with <Semaphore x="615677" class="Medicine" value="gemcitabine" score="0.87" ID="216806">gemcitabine </Semaphore>and <Semaphore x="363530" class="Medicine" value="Cisplatin" score="0.87" ID="251595">cisplatin </Semaphore>on 22/Nov/2012. Approximately two months later, on 21/Jan/2013, the subject developed <Semaphore x="1772585" class="Disease or Finding" value="Cholangitis" score="1.00" ID="C26718">cholangitis </Semaphore>which <Semaphore x="2032500" class="Disease or Finding" value="Hospitalization Required" score="1.00" ID="C50414">required <Semaphore x="3012166" class="MedDRA LLT" value="Hospitalisation" score="1.00" ID="10054112">hospitalization</Semaphore></Semaphore>. No further details were reported. The subject had not received any <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy </Semaphore>and the event remained ongoing at the time of the report. The subjects last dose of investigational product prior to the event was on 10/Jan/2013. The last dose of <Semaphore x="615677" class="Medicine" value="gemcitabine" score="0.87" ID="216806">gemcitabine </Semaphore>and <Semaphore x="363530" class="Medicine" value="Cisplatin" score="0.87" ID="251595">cisplatin </Semaphore>prior to the event was on 17/Jan/2013. Action taken with investigational product was not provided at the time of the report.The investigator reported that there was a reasonable possibility that the event of <Semaphore x="1772585" class="Disease or Finding" value="Cholangitis" score="1.00" ID="C26718">cholangitis </Semaphore>was related to investigational product. <Semaphore x="615677" class="Medicine" value="gemcitabine" score="0.87" ID="216806">Gemcitabine </Semaphore>and <Semaphore x="363530" class="Medicine" value="Cisplatin" score="0.87" ID="251595">cisplatin </Semaphore>were reported as co suspect.</narrativeincludeclinical>
				<sendercomment>Panitumumab is a high-affinity fully human immunoglobulin IgG2 monoclonal antibody that targets the human epidermal growth factor receptor leading to inhibition of EGFr activation.

The event of cholangitis has not been documented as listed or expected in the Amgen Development Core Safety Information for product panitumumab.

Although a temporal association exists, it is not sufficient to establish, or rule out, a causal relationship between panitumumab and the event reported in this case. Additionally, causality is confounded by underlying cholangiocarcinomas and concurrent use of gemcitabine and cisplatin.

This individual case report does not change the safety profile of the product.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>